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Oleoylethanolamide treatment 
affects gut microbiota composition 
and the expression of intestinal 
cytokines in Peyer’s patches of mice
Monica Di Paola1, Elena Bonechi2, Gustavo Provensi2, Alessia Costa3, Gerard Clarke4, 
Clara Ballerini  5, Carlotta De Filippo  6 & M. Beatrice Passani3
The lipid sensor oleoylethanolamide (OEA), an endogenous high-affinity agonist of peroxisome 
proliferator-activated receptor-α (PPAR-α) secreted in the proximal intestine, is endowed with several 
distinctive homeostatic properties, such as control of appetite, anti-inflammatory activity, stimulation 
of lipolysis and fatty acid oxidation. When administered exogenously, OEA has beneficial effects in 
several cognitive paradigms; therefore, in all respects, OEA can be considered a hormone of the gut-
brain axis. Here we report an unexplored modulatory effect of OEA on the intestinal microbiota and on 
immune response. Our study shows for the first time that sub-chronic OEA administration to mice fed 
a normal chow pellet diet, changes the faecal microbiota profile, shifting the Firmicutes:Bacteroidetes 
ratio in favour of Bacteroidetes (in particular Bacteroides genus) and decreasing Firmicutes 
(Lactobacillus), and reduces intestinal cytokines expression by immune cells isolated from Peyer’s 
patches. Our results suggest that sub-chronic OEA treatment modulates gut microbiota composition 
towards a “lean-like phenotype”, and polarises gut-specific immune responses mimicking the effect of a 
diet low in fat and high in polysaccharides content.
Gut microorganisms are indispensable for the regulation of the host metabolism by protecting the intestine 
against exogenous pathogens and potentially harmful resident microorganisms. Several mechanisms converge 
to establish a healthy status of the host, which include a constant dialogue between microbiota and intesti-
nal immune system. The intestinal microbial community plays a pivotal role in the development of the innate 
immune system and is essential in shaping adaptive immunity1. In turn, intestinal immune responses regulate the 
composition of the microbiota2,3. The intestinal immune system has particular features to control the proliferation 
and composition of intestinal microbes. Peyer’s patches are gut-associated lymphoid follicles that, by their ability 
to transport luminal antigens and bacteria, can be considered as the immune sensors of the intestine. Peyer’s 
patches functions, such as induction of immune tolerance or defence against pathogens, result from the complex 
interplay between immune cells located in the lymphoid follicles and the follicle-associated epithelium. Hence, 
Peyer’s patches sampling of the lumen is crucial for protective mucosal immune responses4. Dysbiosis disrupts 
gut homeostasis and increases the risk of inflammatory responses and it is now broadly accepted that changes in 
the microbiota are associated with not only intestinal5, but also immunological and metabolic diseases6. In addi-
tion, changes in the microbiota may affect the central nervous system through the gut-brain axis and may contrib-
ute to signs and symptoms of neurological diseases7–10. Diet has a fundamental role in shaping the gut microbiota 
profile; for instance, an animal-fat based diet leads to fall in bacterial diversity and shifts the proportions of the 
two most abundant phyla of gut microbiota, Firmicutes and Bacteroidetes11. On the contrary, a fiber-rich diet 
promotes bacterial diversity that affords an anti-inflammatory outcome, as it ameliorates pathological profiles as 
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for instance in type-2 diabetes12. It has been proposed that diet-induced obesity is associated with dysbiosis that 
creates a permissive gut inflammatory environment13. Although the literature reports some discrepancies regard-
ing how the inflammatory state in the intestine relates to obesity and metabolic diseases, some studies have shown 
that obesity is associated with an increased intestinal inflammation and elevated levels of intestinal TH1 and TH17 
lymphocytes at the relative expense of TH2 and anti-inflammatory T regulatory (Treg) lymphocytes. For instance, 
Treg levels decrease following prolonged high fat diet in mice14,15.
A newly discovered player in the homeostasis of intestinal functions is the endocannabinoid system16. In this 
regard, oleoylethanolamide (OEA) a potent agonist of PPAR-α, has a prominent role in gut physiology17. OEA 
is synthesized in the gastro-intestinal tract and was first described as a fat sensor that mediates satiety18,19. In 
addition, the levels of OEA activation may change in response to inflammation20, diet21,22 or food intake18,23,24. A 
vast literature suggests that endogenous acylethanolamides, signalling through PPAR-α exert a tonic inhibitory 
control on the induction of nociception and inflammation therefore helping to maintain host-defence homeo-
stasis by preventing inappropriate reactions25,26. OEA is mobilized in the proximal intestine after a meal27, but it 
is currently unclear whether it also affects intestinal homeostasis by changing the profile of the microbiota and 
intestinal lymphocytes activity. To answer these questions, we examined the consequences of sub-chronic OEA 
administration on the faecal microbiota profile and intestinal cytokines expression by immune cells of the mouse 
Peyer’s Patches.
Results
OEA treatment decreases body weight and food consumption. As shown in Fig. 1A mice treated 
with OEA (10 mg/kg i.p.) gained significantly less weight than control mice treated with vehicle (2 way Anova 
repeated measures and Bonferroni post hoc test; Fdays×treatment 11,220 = 2.217, P < 0.05 Fdays 11,220 = 6.126, P < 0.001; 
Ftreatment 1,220 = 11.59, P < 0.01; n = 9–13), although this difference was lost on the last day of treatment. The modest 
weight loss was associated with a moderate but significant reduction of food intake (Fig. 1B,C. Unpaired Student’s 
t test; *P < 0.05; **P < 0.01). Hence, mice did not develop tolerance to the anorexic effect of OEA, as previously 
reported in rats19.
Effect of OEA sub-chronic treatment on gut microbiota profiles in mice. In order to evaluate the 
effect of OEA sub-chronic treatment on gut microbiota, we analysed faecal microbial profiles in a subgroup of 
mice before treatment at steady state (T0; n = 14) and after treatment with OEA 10 mg/kg, i.p. for 11 days (OEA_
T11; n = 7). We then compared the microbiota composition of OEA-treated mice with that of vehicle-treated 
mice (VEH_T11 group; n = 7), used as controls.
Alpha diversity was estimated by observed OTUs (a measure of microbial richness), Shannon entropy, a meas-
ure of entropy accounting for both abundance and evenness of bacterial species, Dominance, an index indicating 
whether one taxon dominates the community completely, and Equitability, a measure of the evenness with which 
bacterial species are divided among the taxa (see Methods). Although the differences were not statistical signif-
icant, the observed OTUs showed a trend of increased species richness in OEA-treated mice (T11) compared 
to T0, and a trend of higher microbial diversity (as indicated by Shannon index) after OEA treatment (T11) 
compared to T0 and vehicle-treated mice (Fig. 2A,B). We also observed that no taxon dominates bacterial com-
munity after OEA treatment, as observed by Dominance index, and that no differences in evenness of bacterial 
communities were found among T0, OEA treatment and controls, as observed by Equitability index (Fig. 2C,D).
To evaluate differences in faecal microbiota communities between groups, we analysed beta diversity by using 
Non-metric Multi-Dimensional Scaling (NMDS) and Principal Coordinates Analysis (PCoA) on Bray-Curtis 
distances. Both ordinations showed a clear separation of OEA-treated mice samples with respect to samples at 
T0 and that of vehicle-treated mice (Fig. 2E,F; P = 0.035 PERMANOVA), suggesting an effect of OEA on gut 
microbiota profiles.
We then performed a meta-taxonomic analysis at different taxonomic levels. In Fig. 3, the most abundant 
bacterial phyla and genera (>1%) in mice at T0 and after OEA treatment and in controls at T11 are shown.
Figure 1. Effect of sub-chronic OEA administration on body weight and food consumption. (A) Time course 
of the effects of vehicle (VEH) or OEA (10 mg/kg, i.p.) on body weight change in mice. Two-way ANOVA with 
repeated measures and Bonferroni’s post hoc test; significantly different from vehicle treated mice, *P < 0.05; 
**P < 0.01; (B) Time course of the daily and (C) Cumulative food intake. Student’s T test, *P < 0.05; **P < 0.01; 
n = 9–13 per group.
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Figure 2. Alpha and Beta diversity. (A–D) Alpha diversity measures. Box plots of (A) observed OTUs, (B) 
Shannon index, (C) Dominance, and (E) Equitability calculated for mice groups at T0 = before the treatment, 
after 11 days of OEA treatment (OEA_T11) and after 11 days of vehicle treatment (Vehicle_ T11). Pairwise 
comparisons by using the Wilcoxon rank sum test were not significant. (E-F) Beta diversity measure. (E) PCoA, 
and (F) NMDS based on Bray Curtis dissimilarities. Samples at T0, samples of OEA_T11 and Vehicle_T11 are 
indicated with different colours. P = 0.035 PERMANOVA using the Adonis function with 999 permutations. 
For NMDS, stress value=0.09 indicated a good representation.
Figure 3. Barplot representation of microbial profiles. Relative abundances, on average, at the phylum and 
genus level of the microbiota in mice before the treatment (T0), after OEA and vehicle treatment at T11.
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Linear discriminant analysis Effect Size analysis (LEfSe) showed differentially enriched phyla at T0 and after 
OEA treatment (OEA_T11; Fig. 4A). Firmicutes were enriched at T0 and in vehicle-treated mice at T11 (rela-
tive abundance on average, 52% at T0 and 41% for vehicle treated mice vs 35% after OEA treatment; Fig. 4B). 
Bacteroidetes on the other hand, were enriched at T11 after OEA treatment when compared with both T0 (on 
average, 39% after OEA treatment vs 28% at T0) and with vehicle treated mice at T11 (34%).
At the genus level, we observed that, when compared to T0, OEA treatment enriched the microbiota of 
Bacteroides (on average 16% at T0 vs 34% at T11 of OEA-treated mice), Prevotella (on average 2% at T0 vs 5% at 
T11 of OEA-treated mice), and Parabacteroides (on average 2% at T0 vs 5% at T11 OEA-treated mice; Fig. 4C). 
When compared to vehicle-treated mice, Bacteroides were enriched in OEA-treated mice (34% OEA treated-mice 
vs 15% control mice; Fig. 4D), whereas the observed different abundances of Prevotella and Parabacteroides 
between vehicle- and OEA-treated mice at T11 were not significant (Fig. 4D). Sequence alignments by BLASTn 
indicated that the majority of Bacteroides sequences in microbiota of OEA-treated mice were attributable with 
97–98% of identity (see section “Methods”) to B. acidifaciens and to a lesser extent to B. sartorii.
Furthermore, LEfSe analysis showed that Lactobacillus was significantly reduced after OEA treatment, in com-
parison with either T0 or vehicle-treated mice at T11 (22% vs 49% vs 42%, respectively; Fig. 4C,D). Sequence 
alignments by BLASTn indicated that Lactobacillus sequences were attributable from 97% to 99% of identity to 
different species, especially L. reuteri and L. gasseri, and to a lesser extent to L. murinus and L. johnsonii.
Prediction of functional metabolic profiles of gut microbiota in OEA-treated mice. In order 
to predict how the observed differences in microbial profiles affected by OEA treatment, reflect differentially 
enriched functional pathways in mice, we applied PICRUSt (Phylogenetic Investigation of Communities by 
Reconstruction of Unobserved States). We observed functional classes (KEGG categories) differentially enriched 
in mice at T0 and after OEA treatment at T11 (Fig. 5A). In particular, among the metabolic functions signifi-
cantly enriched in the microbiome of OEA-treated mice compared to T0, we found KEGG categories related to 
amino acids metabolism, (such as arginine and proline metabolism, glycine, serine and threonine metabolism, 
phenylalanine metabolism and tryptophan metabolism), together with functions related to glycan biosynthesis 
and metabolism (including functions related to other glycan degradation and glycosaminoglycan degradation). 
Other significant enriched functions were sphingolipid metabolism, glycosphingolipid metabolism and lipoic 
acid metabolism. Functions related to carbohydrate metabolism (such as butanoate metabolism and propanoate 
Figure 4. Metagenomic biomarker discovery by LEfSe analysis. Differential enriched bacterial taxa at the 
phylum level in gut microbiota of mice (A) before (T0) and after OEA treatment (T11) and (B) of mice treated 
for 11 days with OEA or vehicle- (Vehicle_T11). Differentially enriched bacterial taxa at the genus level in the 
gut microbiota of mice (C) before (T0) and after OEA treatment (T11) and (D) 11 days after OEA (T11) or 
vehicle treatment (Vehicle_T11). In the lower panels, cladograms show the most discriminative bacterial clades. 
Coloured regions/branches indicate differences in the bacterial population structure between the different 
groups. Statistically significant taxa enrichment among groups was obtained with Kruskal-Wallis test among 
classes (Alpha value = 0.05). The threshold for the logarithmic LDA score was 2.0.
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metabolism), and lipid metabolism (such as biosynthesis of unsaturated fatty acids), were reduced in OEA-treated 
mice compared to T0.
When vehicle and OEA treatment were compared at T11 (Fig. 5B), the metabolic functions enriched in the 
microbiome of OEA-treated mice regarded the metabolism of simple sugars and polysaccharides (such as pen-
tose and glucoronate interconversions and other glycan degradation), and sphingolipid metabolism, whereas 
propanoate metabolism was reduced.
OEA sub-chronic treatment modulates cytokines expression in intestinal Peyer’s patches. 
Peyer’s patches, together with small intestine epithelial cells, are thought to be the first station for the discrimina-
tion between pathogens and commensal bacteria. As OEA modified the microbiota profile, we also investigated 
Peyer’s patches response to the sub-chronic administration of OEA. In order to study cytokine production of 
Peyer’s patches isolated cells, we tested two mitogens that activate different immune cell populations. Isolated 
Peyer’s patches cells were incubated in either the lymphocyte mitogen phytohaemmagglutin (PHA), that mainly 
induces IL2, IFNγ and TNFα production by indirect T cell receptor cross linking; the other mitogen tested was 
lipopolysaccharide (LPS) that induces the production of critical proinflammatory cytokines necessary to activate 
immune responses by binding to TLR4 and triggers the NFkB pathway in innate immune cells (e.g. dendritic 
cells, macrophages), lymphocytes and intestinal epithelial cells (IECs, reviewed in28).
As shown in Fig. 6A, a variety of cytokines and chemokines released by lymphocytes were differen-
tially affected by OEA treatment. Cytokine regulation in response to OEA included a significant decrease of 
pro-inflammatory IFNγ, IL6, IL17, IL4, TNFα compared to vehicle treated mice (Unpaired Student’s t test, 
Figure 5. PICRUSt functional analyses. Extended error bar plots representing (A) Microbial pathways 
predicted to be differentially enriched in microbiomes of mice at T0 and after OEA treatment (OEA_T11). (B) 
Microbial pathways predicted to be differentially enriched in microbiomes of mice after OEA treatment (OEA_
T11) versus controls (Veh_T11). Each extended error bar plot indicates the p-value along with the effect size 
and the associated difference in mean proportion and confidence interval for each predicted KEGG function. 
Each bar plot indicates the mean proportion of sequences assigned to the KEGG categories in each group. 
P-values by White’s nonparametric t-test, Storey FDR correction.
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*p < 0.01, **p < 0.001, ***p < 0.0001; n = 5 animals X group). We observed a trend of IL10 increase that did 
not reach statistical significance. Furthermore, OEA decreased the release of the chemokines CXCL1 and CXCL2 
that are required for recruitment of neutrophils during inflammatory responses following bacterial infections and 
injury29. In the presence of LPS, immune cells from Peyer’s patches of OEA-treated mice produced significantly 
less IFNγ, IL6, IL17, whereas no significant differences were observed for the other cytokines and for chemokines 
(Fig. 6B; unpaired Student’s T test, *P < 0.05, **P < 0.01, ***P < 0.001).
Treatment with OEA modifies lymphocytes transcription factor expression. We also evaluated 
if the modulation of lymphocytic cytokines production was due to the activation of different subsets of T lym-
phocytes by analysing the relative expression of cMaf, Tbet, RORc GATA3 and FOXP3, transcription factors that 
affect the functional capabilities
and flexibility of CD4+ T cell subsets30. We found that OEA treatment significantly increased cMaf associ-
ated with TH2 (IL10 producing lymphocytes) and macrophages6,31,32 and decreased RORc (associated with TH17 
lymphocytes) expression (Fig. 7; Unpaired Student’s t test, ***P < 0.001 and **P = 0.03), whereas the observed 
decrease of TH1 associated Tbet, GATA3 (TH2 lineage-specifying factor) and Foxp3 (Treg lineage-specifying fac-
tor) did not reach statistical significance. These results strongly suggest a trend towards TH2 polarization at the 
expenses of TH17, an observation also corroborated by the significant decrease of IL17, IL6 expression in the 
Peyer’s patches of OEA-treated mice.
Figure 6. Changes of cytokines and chemokines secretion in intestinal Peyer’s Patches. Protein production 
was determined by Luminex technology on cells supernatant of OEA- (black column) and vehicle-treated 
mice (withe column). Cell were activated by either PHA (5 µg/ml) (A) or LPS (1 µg/ml) (B). Each histogram 
represents mean value ± SEM of protein concentration (pg/ml) of 12 samples for each group of PHA 
condition from 3 independent experiments and 4 samples for each group of LPS from 1 experiment. Statistical 
significance of the differences between VEH- and OEA-treated mice was analysed using Student’s t-test; 
*P < 0.05, **P < 0.01, ***P < 0.001.
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Discussion
This study shows for the first time that OEA treatment changes the microbiota composition of mice in a way that 
mimics the effect of a diet low in fat and high in polysaccharides content, and is also able to polarise gut-specific 
immune responses. We also confirmed that OEA treatment is associated with the reduction of body weight and, 
in agreement with previously reported results19,23, we observed that the change in body weight was associated 
with a small reduction of food consumption. In our hands, the overall effects of OEA are in line with those 
reported by other authors in rats and mice19,33,34. When comparing our results to those of other authors though, 
OEA treatment did not have the same effect on body weight change at all time points. Different experimental 
settings such as difference in the day time at which OEA was administered, animal strains, single-caging may be 
responsible of the discrepancies.
Compared with steady state (T0) and control treatment (vehicle at T11), sub-chronic OEA treatment mod-
ified microbial profiles in faeces of mice, as observed by analysis of biodiversity. This diversity is reflected in the 
populations of the gut microbiota, as OEA shifted the Firmicutes:Bacteroidetes ratio in favour of Bacteroidetes, 
in particular the genus Bacteroides, and reduced Firmicutes, in particular the genus Lactobacillus. This 
Firmicutes:Bacteroidetes trend was observed for the first time in ob/ob versus lean mice by Ley and co-workers35 
and subsequently in human obese subjects36. These effects of OEA on the microbiota profile are very much like 
those afforded by a fiber-rich diet that promotes the survival of saccharolytic bacteria, such as Bacteroides, able 
to use dietary-derived glycans as energy sources, thanks to the high number of glycoside hydrolases and polysac-
charide lyases (reviewed in11,37).
In agreement with the body weight reduction induced by OEA, a previous study demonstrated that Bacteroides 
and Prevotella are negatively correlated with fat mass development in diet-induced obese mice38. Relevant to our 
study, within Bacteroides genus, the observed enrichment of B. acidifaciens is associated with lower body weight, 
fat mass and improvement of insulin resistance in hepatic autophagy-related gene 7 (Atg7)-deficient mice39. Of 
note, B. acidifaciens promoted the expression of PPAR-α in epididymal adipose tissue39.
On the other hand, a high fat/high refined carbohydrates diet leads to a prevalence of Firmicutes40. In our 
study, the reduction of Lactobacillus genus following OEA treatment involved L. murinus, L. johnsonii, and in 
particular L. gasseri and L. reuteri. In humans and animals, weight modifications, either weight loss or gain, were 
significantly associated with different Lactobacillus species and strains, and these modifications are believed to 
be host-specific as reported by two meta-analyses41,42. Some studies have shown that in pigs, turkeys and rats, 
L. reuteri induced a significant weight gain41,43,44, and in some cases, even if there is no clear evidence, an associa-
tion with obesity45–47. Thus, our findings suggest, in the opposite direction, an association between OEA-induced 
diminished weight gain and reduced abundance of some commensal bacteria, such as Lactobacillus, but not 
of Bacteroides, in particular B. acidifaciens. Overall, our results suggest that OEA sub-chronic treatment shifts 
gut microbiota towards a “lean-like phenotype”. Prediction analysis (PICRUSt) of the metabolic pathways by 
metagenomic data as well suggests that OEA-induced shift of microbial profiles produces significant modifica-
tions of microbiome functions, suggesting relevant consequences on host metabolism and intestinal immune 
homeostasis.
OEA treatment, by activating PPAR-α, not only induces food-satiety and a modest weight loss19,34, as con-
firmed by our results, but it also enhances lipid utilization by stimulating fatty acid uptake, intracellular transport 
and lipolysis, fat oxidation, and can also modulate lipid levels in tissues and circulation17,34. In addition, OEA 
participates in the physiologic inhibition of intestinal motility48 presumably in a PPAR-α independent man-
ner49, enhances long-chain fatty acid uptake in enterocytes39, and increases intestinal epithelial cells resistance50. 
These metabolic and homeostatic effects of OEA may change the intestinal environment and the ecological fit-
ness of bacterial community, favouring the enrichment of Bacteroides at the expenses of other genera, such as 
Lactobacillus. We cannot exclude though, that the rapid effect on body weight induced by OEA contributes to the 
microbiota modification. Further studies should be performed to understand the role of direct and/or indirect 
mechanisms on the intestinal microbiota.
Several lines of evidence suggest that endogenous ligands of PPAR-α exert a tonic inhibitory control over the 
induction of inflammatory responses25. Whereas the anti-inflammatory effects of the PPAR-α agonist palmitoy-
lethanolamide (PEA) are well documented20, less studied is the direct contribution of OEA to the production of 
inflammatory or regulatory cytokines, even more so in the gut-associated lymphoid tissues.
We found that OEA profoundly affects the polarization of TH lymphocytes in the Peyer’s patches towards 
an anti-inflammatory profile, in agreement with previous reports that indicated how stimulation of PPAR-α 
Figure 7. Ex vivo analysis of cells isolated from intestinal Peyer’s Patches. Relative expression of transcription 
factors by real time PCR. The graph shows mean values ± SD of 4 vehicle-treated (dark column) and 4 OEA-
treated mice (light column) of two independent experiments. Expression of transcription factors is reported as 
ratio to ubiquitin. Student’s t-test, **p = 0.03; ***p < 0.001.
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competes with other transcription factors that are major mediators of inflammatory response in lymphocytes, 
monocyte and macrophages51,52. Furthermore, it is well established that PPAR-α genetic deletion results in 
increased TH1/TH17 response of cells isolated from the intestine lamina propria at steady state conditions and 
the condition is exacerbated in colitis53. Our observation of the concomitant change in microbiota and Peyer’s 
patches environment in vivo suggests a double, if not related, effect of OEA in the intestine, that may be exploited 
to counteract obesity induced regional and systemic inflammation54, balancing the reduction of a tolerant milieu 
associated with skewing toward TH1/TH17 immune profile in the liver, adipose and muscle tissue13. Immune 
responses are orchestrated by the production of pro- and anti-inflammatory cytokines, as the lymphonodes 
in the Peyer’s patches must continuously distinguish between commensal bacteria and pathogens, with conse-
quences on systemic immunity. Therefore, the fact that OEA is acting on Peyer’s patches immune cells decreasing 
pro-inflammatory cytokines production and, at the molecular level, transcription factors responsible for TH1 and 
TH17 differentiation may be exploited in order to modulate gut inflammation. OEA and PEA in vivo decrease 
plasma and cortical TNFα mRNA levels55 and our experiments add further knowledge to this observation: in 
our hands TNFα, that in turn induces CXCL1 and CXCL2 production, is down modulated when Peyer’s patches 
derived cells are stimulated with PHA, but not with LPS, suggesting that OEA is promoting a less inflammatory 
mileu, without significantly affecting innate immune response and the ability of neutrophils recall, when nec-
essary. In the future, it would be of interest to check if OEA anti-inflammatory effect is present in all intestinal 
regions and associated to immune cells, as in fact these may not behave in the same way as cells isolated from 
Peyer’s patches56.
Several intriguing questions remain unanswered as for instance whether the homeostatic effects of OEA on 
Peyer’s patches immune cells responses and microbiota are independent phenomena or whether they influence 
each other. Our results can be explained by two equally valid hypotheses: (i) the induction of a tolerogenic milieu 
in itself determines differences in the microbiome, or (ii) OEA-induced changes in the microbiome primes 
anti-inflammatory responses. There is evidence that bioactive lipids (e.g. palmytoylethanolamide, anandamide, 
short chain fatty acids) participate in physiological processes correlated with the maintenance of gut-barrier 
function, inflammation and energy metabolism20,57,58. Dysregulation of the endocannabinoid system might play 
a crucial role in the etiopathogenesis of intestinal disorders59. Enhancing endogenous OEA synthesis could rep-
resent a new therapeutic strategy to treat such diseases.
Overall, the present study stimulates future investigation addressed at solving the causal effects, also measur-
ing the microbial metabolites produced by OEA treatment, to provide further useful insights on role of OEA in 
the gut-brain axis.
Methods
Animals. SV129 male mice aged 8–12 weeks were bred in our colony in the animal facility where they were 
single-housed in macrolon cages at 20–24 °C. Mice were allowed free access to chow pellets (Mucedola, Milano 
Italy) and water, and kept on a 12-h-light/-dark cycle (light started at 7:00 am). All experimental manipulations 
were performed in strict compliance with the EEC recommendations for the care and use of laboratory animals 
(2010/63/EU) approved by the Animal Care Committee of the Dipartimento di Scienze della Salute, Universitá di 
Firenze (I). Ethical policy of the Universitá di Firenze complies with the Guide for the Care and Use of Laboratory 
Animals of the Council Directive of the European Community (2010/63/EU) and the Italian Decreto Legislativo 
26 (13/03/2014). Every effort was made to minimize animal suffering and to reduce the number of animals used. 
Mice were handled for at least 4 days before experiments begun, to let them acclimatise to human contact. Body 
weight and food consumption were measured daily, starting the day before administration of OEA or vehicle. 
OEA (Tocris Bioscience, UK) was dissolved in saline/polyethylene glycol/Tween80 (90/5/5, v/v) and administered 
at a dose of 10 mg/kg i.p. 30 min before lights off, once daily for 11 days. The dose of OEA was within the range of 
i.p. doses that have been reported in the literature and that do not cause harmful or unwanted side effects19,60–62. 
Mice were weighted and food consumption measured in the morning, and faecal pellets collected right after.
Faecal samples collection and bacterial genomic DNA extraction. Faeces was collected (i) at 
steady state (T0) from each mice group, (ii) after 11 days of OEA treatment (OEA_T11), and (iii) after 11 days 
of vehicle-treatment (Vehicle_T11). For each group of mice, the pellets were collected in sterile conditions and 
stored at −80 °C until extraction of nucleic acids. The bacterial genomic DNA extraction was carried out with 
DNeasy PowerLyzer PowerSoil Kit (Qiagen, Hilden, Germania) following the manufacturer’s instructions. DNA 
quality was assessed by gel electrophoresis and spectrophotometry, measuring OD 260/280.
16S Ribosomal RNA Gene Amplicons preparation and Illumina MiSeq sequencing. Library of 
16S rRNA gene amplicons was prepared by IGA Technology Services (Udine, Italy) through amplification of the 
V3-V4 hypervariable region by using specific-barcoded primers with overhang adapters. The standard proto-
col was followed according to the 16S metagenomic sequencing library preparation guide from Illumina (Part 
#15044223 Rev. B; https://support.illumina.com/). Pooled V3-V4 amplicon libraries were sequenced using the 
Illumina MiSeq platform.
Data Analysis. Sequence data are available at http://www.ebi.ac.uk/ena/data/view/ PRJEB26276, under the 
accession number PRJEB26276. The 300-bp paired-end reads obtained from Illumina MiSeq platform for each 
sample were demultiplexed and quality checked using FastQC 0.11.5. Reads were further processed using the 
MICCA pipeline (version 1.6, ttp://compmetagen.github.io/micca/)63. Briefly, Illumina paired-end reads was 
merged by using the mergepairs function. Forward and reverse primers was trimmed, and reads did not contain 
the forward or the reverse primer was discarded, as well as both sequences preceding the forward or succeed-
ing the reverse primers was removed. Quality filtering were performed by using mica-filter (according to the 
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maximum allowed expected error rate % reported in filterstats), truncating reads shorter than 300 nt (quality 
threshold = 18), in order to produce high-quality reads. Denovo sequence clustering, chimera filtering and taxon-
omy assignment were performed by micca-otu-denovo. Operational Taxonomic Units (OTUs) were assigned by 
clustering the sequences with a threshold of 97% pair-wise identity. The representative sequences were classified 
using the RDP classifier version 2.7 against RDP 11 database (update 5) of 16S rRNA. Template-guided multiple 
sequence alignment was performed using PyNAST (version 0.1) against the multiple alignment of the Greengenes 
16S rRNA gene database (release 13_05) and filtering at 97% similarity. A total of 3570 Operational Taxonomic 
Units (OTUs) were assigned by clustering the sequences with a threshold of 97% pair-wise identity. OUT tables 
for each taxonomic level were created by mica-tabletotax and used for further statistical analysis.
For Bacteroides and Lactobacillus genera, depth at species level was obtained by sequence alignment using 
Basic Local Alignment Search Tool nucleotide (BLASTn) software in the National Center for Biotechnology 
Information (NCBI) database. The highest percentage of identity (Query cover 100–99% and Identity 99 or 95%). 
Expectation value (E-value) was used to select significant BLAST hits, keeping only outcomes with the lowest 
E-value (minimal E-value of 10−3).
Alpha diversity was estimated by observed OTUs (a measure of microbial richness), Shannon entropy (a 
measure of entropy accounting for both abundance and evenness of bacterial species), Dominance (1-Simpson 
index), and Equitability (Shannon diversity divided by the logarithm of number of taxa), by using Paleontological 
Statistics Software Package (PAST3 v.3.12). Beta diversity was performed to evaluate differences in overall bacte-
rial communities by Principal Coordinates Analysis (PCoA) and Non-metric Multidimensional Scaling (NMDS), 
based on Bray-Curtis dissimilarities, using the phyloseq package of the R software suite. The significance of 
between-groups differentiation on Bray-Curtis dissimilarity was assessed by PERMANOVA using the adonis() 
function of the R package vegan with 999 permutations.
To infer the functional pathways (KEGG categories) that differ between mice groups (treated with OEA vs 
control mice), we applied Phylogenetic Investigation of Communities by Reconstruction of Unobserved States- 
PICRUSt64 on 16S rDNA sequencing data set. We obtained the final output from metagenome prediction as an 
annotated table of predicted gene family counts for each sample, where the encoded function of each gene family 
be orthologous groups or other identifiers such as KEGG orthologs (KOs).
Metagenomic biomarker discovery and related statistical significance were assessed by using the linear discri-
minant analysis (LDA) effect size (LEfSe) method, based on the bacterial relative abundances. In LEfSe, Kruskal–
Wallis rank-sum test is used to identify significantly different taxa abundances among groups of mice, and LDA 
to estimate the size effect of each feature. An alpha significance level of 0.05, either for the factorial Kruskal-Wallis 
test among classes or for the pairwise Wilcoxon test between subclasses, was used. A size-effect threshold of 2.0 
on the logarithmic LDA score was applied for discriminative microbial biomarkers. LEfSe was also performed on 
PICRUSt data to discover bacterial functional biomarkers among groups of mice based on different treatments.
For PICRUSt analysis, statistical analysis and visualization of results were performed by using STAMP pack-
age (Statistical Analysis of Metagenomic and other Profiles; version Profiles65; version 2.1.3). Multiple compari-
son testing was performed using non-parametric Kruskal Wallis test. Two-group comparison was performed by 
White’s non-parametric t-test, using an alpha of 0.05, with Storey false discovery rate correction.
Peyer’s patches isolation and cytokines determination. Mice were sacrificed by cerebral dislocation 
without anaesthesia. Peyer’s Patches were freshly isolated from the intestine and transferred in a 15 ml tube with 
PBS + 1% Pen/Strep (Lonza, Germany) to prevent drying. Peyer’s patches were digested with collagenase D (1 mg/ml) 
(Sigma-Aldrich, USA) in a 37 °C and 5% CO2 incubator for 5 minutes. All Peyer’s patches were transferred in a 
70 µm cell strainer (Falcon, USA) placed over 50 ml tube and mechanically dissociated. During dissociation filters 
were washed with RPMI + 1% PEN/Strep. Peyer’s patches-single cells flowed through the filter and were sus-
pended in 15 ml of RPMI, 10% FBS, 1%Pen/Strep, 0,01% beta-mercaptoethanol, 1% L-glutammin, 1% Na-Pir and 
1% Hepes (complete medium). Cells were centrifuged at 1300 rpm at room temperature for 10 minutes, then the 
supernatant was discarded and pellets were suspended in complete medium. Peyer’s patches cells were counted 
with Thomas chamber using trypan blue dye exclusion. Cells were plated at the concentration of 1 × 105 cells/100 
µl (1 × 106 cells/ml) in 96-well plate in the presence of PHA (5 ug/ml), LPS (1 ug/ml) (Sigma-Aldrich, USA) or 
vehicle for 48 h, in a 37 °C and 5% CO2 incubator. After incubation cell supernatants were collected for the deter-
mination of the following soluble factors: IFNγ, IL4, IL6, IL10, IL17, TNFα, CXCL1, CXCL2, by Luminex 
Technologies (Procartaplex, Life Technologies, USA).
RNA extraction. Peyer’s patches cells were transferred in QIAzol (QIAGEN, Germany) lysis buffer, for 
RNA extraction. RT-PCR was carried out on 0.5–1 ng total RNA using Quantitec Reversion Transcription kit 
(QIAGEN, Germany) as first-strand primer. Real-time quantitative PCR was performed using TaqMan Universal 
PCR Master Mix, according to the manufacturer’s instructions (ThermoFisher Scientific, USA). The cDNA 
fragments corresponding to mouse Tbet, Rorc, GATA3, cMaf and Foxp3 were amplified using specific pairs of 
primers (Life Technologies, USA). All samples were run in triplicate on 96-well using optical PCR plates (Life 
Technologies, USA). Data were expressed as arbitrary units relative to expression of the gene encoding ubiquitin. 
The reference gene for RT-PCR, ubiquitin, was selected among others normally in use that are not involved in 
the process under examination, e.g. GADPH-R, 16S rRNA. To date no published indications are available for PP. 
Differences were revealed by unpaired Student’s t test, and significance was set at P < 0.05.
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